trending Market Intelligence /marketintelligence/en/news-insights/trending/HjfEw9cuQhFcQZyaYRxiEA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

US appeals court overturns $10.4M judgment against Calmare Therapeutics

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


US appeals court overturns $10.4M judgment against Calmare Therapeutics

Calmare Therapeutics Inc. said a U.S. appeals court overturned a previous $10.4 million judgment against the company for allegedly violating a contractual agreement.

South Korea's GEOMC Co. Ltd. had sued Calmare in 2014 in the U.S. District Court for the District of Connecticut for failing to comply with the terms of a security agreement.

Under the alleged agreement, GEOMC was expected to manufacture Fairfield, Conn.-based Calmare's pain therapy device in exchange for a security interest in the devices.

In 2017, the district court awarded GEOMC monetary damages of $4.7 million and pre-judgment interest of $5.7 million, for a total of $10.4 million. Calmare appealed the ruling.

The U.S. Court of Appeals for the 2nd Circuit reversed the ruling and remanded the case to the district court for further proceedings.

Both the parties have until March 26 to seek reconsideration of the appeal court's judgment.